Efficacy of Sacubitril/Valsartan Sodium Combined with Simvastatin in Treating Chronic Heart Failure with Arrhythmia and Its Effects on IL-6, IL-8, and TNF-α
Sacubitril/Valsartan and Simvastatin in Heart Failure with Arrhythmia
Abstract
Background: To explore, in conjunction with clinical practice, the efficacy of different pharmacological treatment regimens for patients with chronic heart failure complicated by arrhythmia, and their effects on inflammatory factor levels.
Methods: A total of 96 patients with chronic heart failure and arrhythmia treated at our hospital from June 2022 to January 2025 were selected and randomly assigned by envelope method into a combination therapy group and a simvastatin group. The simvastatin group received simvastatin monotherapy, while the combination group was treated with sacubitril/valsartan sodium plus simvastatin. Clinical efficacy was compared between the two groups. Cardiac function, inflammatory factors, arrhythmia episodes, blood lipid levels, and oxidative stress markers were assessed before and after treatment. Adverse reactions in both groups were also observed.
Results: The overall effective rate in the combination therapy group (93.75%) was significantly higher than that in the simvastatin group (72.92%) (χ2=7.500, P=0.006). After treatment, the combination group exhibited higher LVEF and lower LVESD and LVEDD levels compared to the simvastatin group (P<0.05). Serum levels of inflammatory factors (IL-6, IL-8, TNF-α) were significantly lower in the combination group than in the simvastatin group after treatment (P<0.05). Both the duration and frequency of arrhythmia episodes were reduced in the combination group compared to the simvastatin group (P<0.05). Post-treatment, LDL-C, TG, and TC levels were lower, and HDL-C was higher in the combination group than in the simvastatin group (P<0.05). MDA and SOD levels were also lower in the combination group after treatment (P<0.05). The incidence of adverse reactions was lower in the combination group (3.33%) compared to the simvastatin group (22.92%) (χ2=5.352, P=0.021).
Conclusion: For patients with chronic heart failure and arrhythmia, combined therapy with sacubitril/valsartan sodium and simvastatin demonstrates significant efficacy. It can alleviate inflammatory responses, improve cardiac function, reduce the frequency and duration of arrhythmia episodes, optimize lipid profiles and stress responses, and decrease adverse reactions. This approach is worthy of further clinical promotion.
References
2. Rogers C, Bush N. Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management. Nurs Clin N Am 2015; 50(4): 787-99.
3. Sun Y, Miao B, Cao Y, Cui J, Da Y, Qi L, et al. Significance of plasma TGF-beta1 level detection in patients with T2DM with heart failure. J Med Biochem 2024; 43(5): 704-10.
4. Zhou W, Yang X, Jin J, Cheng M, Li Y, Bai Y, et al. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 2024; 56(1): 181-90.
5. Yao X, Xie R, Cao Y, Tang J, Men Y, Peng H, et al. Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J Nanobiotechnol 2021; 19(1): 311.
6. Pang S, Geng C, Fan Z, Hou M, Mao H, Tao S, et al. Synergistic Effect of Layered Double Hydroxides Nanodosage Form to Induce Apoptosis and Ferroptosis in Breast Cancer. Int J Nanomed 2024; 19: 4199-215.
7. Wang Y, Hill JA. Electrophysiological remodeling in heart failure. J Mol Cell Cardiol 2010; 48(4): 619-32.
8. Luo M, Anderson ME. Mechanisms of altered Ca(2)(+) handling in heart failure. Circ Res 2013; 113(6): 690-708.
9. Zhihao L, Jingyu N, Lan L, Michael S, Rui G, Xiyun B, et al. SERCA2a: a key protein in the Ca(2+) cycle of the heart failure. Heart Fail Rev 2020; 25(3): 523-35.
10. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005; 365(9474): 1877-89.
11. Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gheorghiade M, et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ-Heart Fail 2010; 3(5): 596-605.
12. Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. Esc Heart Fail 2019; 6(6): 1105-27.
13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DJ, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16): e147-239.
14. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol 2020; 76(6): 719-34.
15. Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol 2020; 17(10): 641-55.
16. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 2013; 15(1): 291.
17. Docherty KF, Vaduganathan M, Solomon SD, McMurray J. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. Jacc-Heart Fail 2020; 8(10): 800-10.
18. Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 2016; 133(11): 1115-24.
19. Norre T, Grimm D, Simonsen U. Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic Clin Pharmacol 2022; 130(4): 425-38.
20. Guglin M. Sacubitril/valsartan in PARADIGM-HF. Lancet Diabetes Endo 2017; 5(7): 494-5.
21. Singh J, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC. Sacubitril/valsartan: beyond natriuretic peptides. Heart 2017; 103(20): 1569-77.
22. Huang E, Bernard ML, Elise HA, Khatib S, Polin GM, Rogers PA, et al. Sacubitril/valsartan: An antiarrhythmic drug? J Cardiovasc Electr 2022; 33(11): 2375-81.
23. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ-Heart Fail 2016; 9(3): e002744.
24. Perrone-Filardi P, Paolillo S, Agostoni P, Basile C, Basso C, Barilla F, et al. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. Eur J Intern Med 2022; 102(8-16.
25. Rohde LE, Claggett BL, Wolsk E, Packer M, Zile M, Swedberg K, et al. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ-Heart Fail 2021; 14(3): e008052.
Copyright (c) 2025 Jingjing Li, Zhihua Wang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.